Trinity Biotech plc (TRIB) is a publicly traded Healthcare sector company. As of May 21, 2026, TRIB trades at $0.59 with a market cap of $11.54M and a P/E ratio of 0.00. TRIB moved +6.65% today. Year to date, TRIB is -20.85%; over the trailing twelve months it is -25.11%. Its 52-week range spans $0.48 to $3.44. Rallies surfaces TRIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in TRIB news today?
Trinity Biotech’s Enhanced EpiCapture Test Achieves 85% AUC in 750-Sample Study: Trinity Biotech’s enhanced EpiCapture prostate cancer test delivered clinical accuracy (AUC) of 85% in a 750-sample study using a new machine learning algorithm incorporating patient ethnicity. The company plans to commercialize the test as a Laboratory Developed Test through its New York State certified reference lab.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 17.80K (~$924.52K) on Feb 18, 2004.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 92.00K (~$4.82M) on Feb 17, 2004.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 65.20K (~$3.39M) on Feb 13, 2004.
TRIB Analyst Consensus
TRIB analyst coverage data. Average price target: $0.00.
Common questions about TRIB
What changed in TRIB news today?
Trinity Biotech’s Enhanced EpiCapture Test Achieves 85% AUC in 750-Sample Study: Trinity Biotech’s enhanced EpiCapture prostate cancer test delivered clinical accuracy (AUC) of 85% in a 750-sample study using a new machine learning algorithm incorporating patient ethnicity. The company plans to commercialize the test as a Laboratory Developed Test through its New York State certified reference lab.
Does Rallies summarize TRIB news?
Yes. Rallies summarizes TRIB news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is TRIB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TRIB. It does not provide personalized investment advice.
